Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Previous close
$18.55
−$1.60 · -7.94%
Regular session · ET · Market data may be delayed.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Day range
Current $18.55
52-week range
Current $18.55
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
49
Mixed
Risk
52
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Day range
Current $18.55
52-week range
Current $18.55
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.72B USD | 2.7B USD | 2.84B USD | 2.84B USD | 3.06B USD |
| Cost of goods sold | 2.3B USD | 2.16B USD | 2.25B USD | 2.11B USD | 2.45B USD |
| Gross profit | 425.8M USD | 534.2M USD | 590.6M USD | 724.4M USD | 604.4M USD |
| Selling, general, and administrative | 456.4M USD | 560.7M USD | 448.1M USD | 416.1M USD | 303.1M USD |
| Operating expenses | 456.4M USD | 696.1M USD | 558.6M USD | 537.3M USD | 490.1M USD |
| Interest expense | 91.4M USD | 123.8M USD | 69.8M USD | 200K USD | 200K USD |
| Depreciation and amortization | 78M USD | 86.9M USD | 98M USD | 93.6M USD | 166.3M USD |
| Operating income | −30.6M USD | −161.9M USD | 32M USD | 187.1M USD | 114.3M USD |
| Net income | −986.2M USD | −328.5M USD | −25.2M USD | 186.2M USD | 98M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.44
26.36% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR106.38M0.11%98.7B USD0.06%$131.25-2.53%
Vanguard Morningstar Total Stock Market ETFVTI50.38M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM48.32M0.07%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF22.95M0.02%30.2B USD0.05%$211.44-3.21%
Vanguard Morningstar Small-Cap ETFVB22.75M0.01%78.7B USD0.03%$270.68-2.56%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM17.37M0.11%15.29B USD0.03%$50.99-2.58%
Invesco S&P SmallCap Momentum ETFXSMO17.06M0.66%2.48B USD0.35%$73.55-3.17%
iShares Russell 2000 Value ETFIWN16.95M0.13%13.05B USD0.24%$198.84-2.08%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap ETFVB
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Invesco S&P SmallCap Momentum ETFXSMO
iShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.